secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALVELLA THERAPEUTICS, INC. (PVLA)
CIK:        0001583648
Form:       8-K
Filed at:   2026-02-26T23:59:59+00:00
Accession:  0001104659-26-020667
Event type: other_material
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palvella Therapeutics raises ~$187.3M in public offering of 1.6M shares at $125/sh
--------------------------------------------------------------------------------

- Underwriting agreement with TD Securities, Cantor Fitzgerald, and Stifel for 1,600,000 shares at $125.00 each.
- Underwriters have 30-day option to purchase up to an additional 240,000 shares at same price.
- Net proceeds estimated at $187.3M after underwriting discounts and expenses.
- Proceeds to support QTORIN rapamycin and pitavastatin programs, R&D, and working capital.
- Closing expected on or about February 27, 2026, subject to customary conditions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1583648/000110465926020667/0001104659-26-020667-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1583648/000110465926020667/tm2534019d6_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-020667

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer